Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Non-Current Liabilities: 2021-2025

  • ARS Pharmaceuticals' Total Non-Current Liabilities was N/A to $221.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.4 million, marking a year-over-year change of. This contributed to the annual value of $16.6 million for FY2021, which is N/A change from last year.
  • Per ARS Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $221.4 million for Q3 2025, which was up 84.88% from $119.7 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Total Non-Current Liabilities peaked at $221.4 million during Q3 2025, and registered a low of $16.6 million during Q4 2021.
  • In the last 1 years, ARS Pharmaceuticals' Total Non-Current Liabilities had a median value of $170.6 million in 2025 and averaged $170.6 million.